SAN FRANCISCO, Mar. 8, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Oppenheimer 28th Annual Healthcare Conference on March 20-21, 2018 in New York City.
Denise Bevers, Co-Founder and Chief Operating Officer, will present and be available for one-on-one meetings at which investors will have the opportunity to discuss key therapeutic programs in development and upcoming milestones.
Date: Wednesday, March 21, 2018
Time: 2:10 – 2:40 PM EDT (11:10 – 11:40 AM PDT)
Location: The Westin New York Grand Central, Track 61 room
An archived version of the webcast will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events/.
About Kindred Biosciences
Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.